𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P.17.7 REACTIVATION OF HBV INFECTION IN PATIENTS WITH LYMPHOMA TREATED WITH CHEMOTHERAPY CONTAINING OR NOT RITUXIMAB

✍ Scribed by Morisco, F.; Pugliese, N.; Guarino, M.; Rea, M.; Vitiello, A.; Clery, E.; Ferraiuoli, C.; Donnarumma, L.; Raimondo, M.; Loperto, I.; Cossiga, V.; Caporaso, N.; Pane, F.; Picardi, M.

Book ID
122276537
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
98 KB
Volume
46
Category
Article
ISSN
1590-8658

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Retracted: Outcome and immune reconstitu
Retracted: Outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen
✍ Chee-Kin Hui; Winnie W. Cheung; Kar-Wai Leung; Vincent C. C. Cheng; Bone S. F. T πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 147 KB

Whether preemptive anti-hepatitis B virus (HBV) therapy should be considered in all hepatitis B surface antigen (HBsAg)-negative patients with occult HBV infection receiving alemtuzumabcontaining chemotherapy is uncertain. We determined the outcome and effect on HBV-specific immunity of an alemtuzum

P168 Hepatitis B virus reactivation in a
P168 Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with immuno-chemotherapy (including fludarabine and rituximab)
✍ Zs. Ujj; L. RejtΓΆ; I. Tornai; A. Kiss; B. Telek; Gy. RemΓ©nyi; P. Ilonczai; M. Ud πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 45 KB

was longer on retreatment (11 months) than at first treatment (6 months). It is of special interest, that this patient was 83 years old when treated first with radioimmunotherapy and tolerated it on both occasions without side effects or severe cytopenias. In another patient with severe accompanying